SCHEMBL6555530

SCHEMBL6555530

CCS(=O)(=O)N[C@H](C(=O)NCCc1ccc(OCCCc2ccc(F)cc2)c(OC)c1)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
ATM Q13315 1/20 0.46
ALDH1A1 P00352 2/20 0.45
ADRB2 P07550 1/20 0.43
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
MAPT P10636 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PLAAT3 P53816 1/20 0.43
PLAAT5 Q96KN8 1/20 0.43
PLAAT2 Q9NWW9 1/20 0.43
PLAAT4 Q9UL19 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6555145 0.92 ALDH1A1 (0.48) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL6554951 0.92 ALDH1A1 (0.48) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL13350353 0.88 KMT2A (0.51) SMN1; SMN2LMNAKMT2AMEN1ALDH1A1
SCHEMBL6554873 0.88 SMN1; SMN2 (0.48) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL6554864 0.88 SMN1; SMN2 (0.48) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL6554633 0.87 KDM4E (0.50) SMN1; SMN2LMNAKMT2AMEN1ADRB2
SCHEMBL6554629 0.87 KDM4E (0.50) SMN1; SMN2LMNAKMT2AMEN1ADRB2
SCHEMBL6555077 0.86 ALDH1A1 (0.46) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL6555072 0.86 ALDH1A1 (0.46) SMN1; SMN2LMNAKMT2AMEN1ATM
SCHEMBL7157479 0.86 LMNA (0.44) SMN1; SMN2LMNAKMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135369-B1 ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2004-02-25 EP disclosed
US-6538159-B2 For use in protecting plants against infestation by phytopathogenic microorganisms SYNGENTA PARTICIPATIONS AG (CH) 2003-03-25 US disclosed
US-20020099241-A1 For use in protecting plants against infestation by phytopathogenic microorganisms SYNGENTA PARTICIPATIONS AG (CH) 2002-07-25 US disclosed
EP-1135369-A2 ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDES Syngenta Participations AG (CH) 2001-09-26 EP disclosed
WO-2000032569-A2 ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099241-A1 For use in protecting plants against infestation by phytopathogenic microorganisms CBR1, CBR3, MSR1 SMN1; SMN2 3433/4885LMNA 3204/4885KMT2A 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.